Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Leslie A, Fecher"'
Autor:
Douglas B. Johnson, Michael B. Atkins, Cassandra Hennessy, Trisha Wise-Draper, Hannah Heilman, Joy Awosika, Ziad Bakouny, Chris Labaki, Renee Maria Saliby, Clara Hwang, Sunny R. K. Singh, Nino Balanchivadze, Christopher R. Friese, Leslie A. Fecher, James J. Yoon, Brandon Hayes-Lattin, Mehmet A. Bilen, Cecilia A. Castellano, Gary H. Lyman, Lisa Tachiki, Sumit A. Shah, Michael J. Glover, Daniel B. Flora, Elizabeth Wulff-Burchfield, Anup Kasi, Saqib H. Abbasi, Dimitrios Farmakiotis, Kendra Viera, Elizabeth J. Klein, Lisa B. Weissman, Chinmay Jani, Matthew Puc, Catherine C. Fahey, Daniel Y. Reuben, Sanjay Mishra, Alicia Beeghly-Fadiel, Benjamin French, Jeremy L. Warner, COVID-19 and Cancer Consortium
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 s
Externí odkaz:
https://doaj.org/article/69fb2be87d9e4455bca96362eb3128f6
Autor:
Alexander M. Balinski, Alexi L. Vasbinder, Connor C. Kerndt, Tonimarie C. Catalan, Nathan P. Parry, Rafey A. Rehman, Pennelope Blakely, Raymond Y. Yeow, Monika J. Leja, Christopher D. Lao, Leslie A. Fecher, Salim S. Hayek
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2356-2367 (2023)
Abstract Background Cardiac metastasis of melanoma is rare and typically diagnosed post‐mortem. Here we perform a retrospective cohort study and systematic review of patients with metastatic melanoma to characterize prevalence, clinical characteris
Externí odkaz:
https://doaj.org/article/923ccc9b39a64ccc8c8887ffde6c4197
Autor:
Melissa Y.Y. Moey, Cassandra Hennessy, Benjamin French, Jeremy L. Warner, Matthew D. Tucker, Daniel J. Hausrath, Dimpy P. Shah, Jeanne M. DeCara, Ziad Bakouny, Chris Labaki, Toni K. Choueiri, Susan Dent, Nausheen Akhter, Roohi Ismail-Khan, Lisa Tachiki, David Slosky, Tamar S. Polonsky, Joy A. Awosika, Audrey Crago, Trisha Wise-Draper, Nino Balanchivadze, Clara Hwang, Leslie A. Fecher, Cyndi Gonzalez Gomez, Brandon Hayes-Lattin, Michael J. Glover, Sumit A. Shah, Dharmesh Gopalakrishnan, Elizabeth A. Griffiths, Daniel H. Kwon, Vadim S. Koshkin, Sana Mahmood, Babar Bashir, Taylor Nonato, Pedram Razavi, Rana R. McKay, Gayathri Nagaraj, Eric Oligino, Matthew Puc, Polina Tregubenko, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Thorvardur R. Halfdanarson, Dimitrios Farmakiotis, Elizabeth J. Klein, Elizabeth V. Robilotti, Gregory J. Riely, Jean-Bernard Durand, Salim S. Hayek, Lavanya Kondapalli, Stephanie Berg, Timothy E. O'Connor, Mehmet A. Bilen, Cecilia Castellano, Melissa K. Accordino, Blau Sibel, Lisa B. Weissmann, Chinmay Jani, Daniel B. Flora, Lawrence Rudski, Miriam Santos Dutra, Bouganim Nathaniel, Erika Ruíz-García, Diana Vilar-Compte, Shilpa Gupta, Alicia Morgans, Anju Nohria
Publikováno v:
Translational Oncology, Vol 34, Iss , Pp 101709- (2023)
Background: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. Objectives: To compare Coronavirus disease 2019 (COVID-19) related co
Externí odkaz:
https://doaj.org/article/9d648aa2b95644a1af71f1806e404101
Autor:
Morgan Homan, Govind Warrier, Christopher D. Lao, Sarah Yentz, Shawna Kraft, Leslie A. Fecher
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III BRAF-mutant melanoma. We describe treatment-related toxicities with adjuvant D+T in a real-world population through a retrospective
Externí odkaz:
https://doaj.org/article/cbccc85ea7e8455ba727545ee78d4caf
Autor:
Vincent T. Ma, Alahendra A. Chamila Perera, Yilun Sun, Merna Sitto, Jessica J. Waninger, Govind Warrier, Michael D. Green, Leslie A. Fecher, Christopher D. Lao
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundStandard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma followed by nivolumab single-agent maintenance therapy. While many patients receive less than 4 doses due to immune-related toxicities
Externí odkaz:
https://doaj.org/article/24f277d92c434e08b89fee9a38e49630
Autor:
Kelly Z. Young, BA, Sara L. Fossum, MD, PhD, Lori Lowe, MD, Tobias Else, MD, Leslie A. Fecher, MD, Hakan Demirci, MD, Kelly B. Cha, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 6, Iss 6, Pp 563-566 (2020)
Externí odkaz:
https://doaj.org/article/a995474b3ca64ffe8e3d7ab477e635fa
Autor:
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M. Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit
Autor:
Ziad, Bakouny, Chris, Labaki, Punita, Grover, Joy, Awosika, Shuchi, Gulati, Chih-Yuan, Hsu, Saif I, Alimohamed, Babar, Bashir, Stephanie, Berg, Mehmet A, Bilen, Daniel, Bowles, Cecilia, Castellano, Aakash, Desai, Arielle, Elkrief, Omar E, Eton, Leslie A, Fecher, Daniel, Flora, Matthew D, Galsky, Margaret E, Gatti-Mays, Alicia, Gesenhues, Michael J, Glover, Dharmesh, Gopalakrishnan, Shilpa, Gupta, Thorvardur R, Halfdanarson, Brandon, Hayes-Lattin, Mohamed, Hendawi, Emily, Hsu, Clara, Hwang, Roman, Jandarov, Chinmay, Jani, Douglas B, Johnson, Monika, Joshi, Hina, Khan, Shaheer A, Khan, Natalie, Knox, Vadim S, Koshkin, Amit A, Kulkarni, Daniel H, Kwon, Sara, Matar, Rana R, McKay, Sanjay, Mishra, Feras A, Moria, Amanda, Nizam, Nora L, Nock, Taylor K, Nonato, Justin, Panasci, Lauren, Pomerantz, Andrew J, Portuguese, Destie, Provenzano, Matthew, Puc, Yuan J, Rao, Terence D, Rhodes, Gregory J, Riely, Jacob J, Ripp, Andrea V, Rivera, Erika, Ruiz-Garcia, Andrew L, Schmidt, Adam J, Schoenfeld, Gary K, Schwartz, Sumit A, Shah, Justin, Shaya, Suki, Subbiah, Lisa M, Tachiki, Matthew D, Tucker, Melissa, Valdez-Reyes, Lisa B, Weissmann, Michael T, Wotman, Elizabeth M, Wulff-Burchfield, Zhuoer, Xie, Yuanchu James, Yang, Michael A, Thompson, Dimpy P, Shah, Jeremy L, Warner, Yu, Shyr, Toni K, Choueiri, Trisha M, Wise-Draper, Catherine, Stratton
Publikováno v:
JAMA oncology.
ImportanceCytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation.ObjectiveTo determine the association of baseline immunosup
Autor:
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Publikováno v:
New England Journal of Medicine. 388:813-823
Autor:
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, David W Craig, David B Solit, Alan H Bryce, Jeffrey A Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A Byron, Mary Jo Pilat, Scott A Boerner, Diane Durecki, William P D Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S Calvert, Emanuel F Petricoin, Leslie Anne Fecher, Christopher Lao, J Paul Eder, Nicholas J Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W Joseph, C Lance Cowey, Jeffrey M Trent
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0248097 (2021)
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-
Externí odkaz:
https://doaj.org/article/ea286e5ad5d3466fb04534c8639561db